AstraZeneca Pharmaceuticals LP
AstraZeneca Pharmaceuticals LP (USA) holds 5 active US FDA Type II Drug Master Files and 4 inactive, has DMF or CEP filings on record for 5 active ingredients, holds 1 active Type IV (excipient) Drug Master File and is linked to 5 FDA-registered manufacturing sites. 41 FDA enforcement records are linked to it.
Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records
Cite as: PharmaTek, “AstraZeneca Pharmaceuticals LP: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/astrazeneca-pharmaceuticals-lp
Overview
AstraZeneca Pharmaceuticals LP is a global, science-led biopharmaceutical company at the forefront of innovative research across various therapeutic areas. It is a subsidiary of AstraZeneca PLC.
Therapeutic areas
Active ingredients with DMF or CEP filings
Substances for which AstraZeneca Pharmaceuticals LP holds, or has held, a US FDA Drug Master File or an EU CEP. A filing is not proof of current supply. Open any ingredient to see all its holders, CAS number and product patent dates.
API / Drug Master Files
AstraZeneca Pharmaceuticals LP holds 5 active (9 total) FDA Type II Drug Master Files. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.
- AZD2292Active2022-10-21
- BUDESONIDEActive2018-10-10
- GOSERELIN ACETATE IMPLANTActive2017-04-21
- GOSERELIN ACETATEActive2017-04-21
- METOPROLOL SUCCINATE EXTENDED RELEASE TABLETSActive2016-12-05
- METOPROLOL SUCCINATE EXTENDED RELEASE/HYDROCHLOROTHIAZIDE 25/12.5,50/12.5 AND100/12.5 TABLETSInactive2014-05-21
- LISINOPRIL BULK DRUGInactive1994-04-08
- ATENOLOL ACETATEInactive1987-08-06
- ATENOLOLInactive1987-03-30
Excipient Drug Master Files
AstraZeneca Pharmaceuticals LP holds 1 active (1 total) FDA Type IV Drug Master File. A Type IV DMF covers an excipient, colourant or flavour, not an active ingredient; these are counted separately from the API filings above.
- POROUS PARTICLESActive2015-05-27
Registered manufacturing sites (5)
Physical sites registered with the US FDA and resolved to AstraZeneca Pharmaceuticals LP, with any EU/UK GMP documents matched to each site. Headquarters and manufacturing locations can differ.
- AstraZeneca Pharmaceuticals LPCoppell, United States · API manufacture
- AstraZeneca Pharmaceuticals LPNewark, United States · Analytical testing · Labelling
- AstraZeneca Pharmaceuticals LPFrederick, United States · API manufacture
- AstraZeneca Pharmaceuticals LPPhiladelphia, United States · Analytical testing · LabellingSite GMP match
- AstraZeneca Pharmaceuticals LPRedwood City, United States · API manufacture
FDA compliance signals
41 FDA enforcement records linked to this company.
- 4832026-06-26
Cleaning / Sanitizing / Maintenance
- recall — Class II2025-10-22
Lack of Assurance of Sterility:
- 4832024-05-31
Complete Test Data
- 4832024-05-31
Procedures not in writing, fully followed
- 4832024-05-31
Investigations of discrepancies, failures
- 4832024-05-31
Complaint Handling Procedure
- 4832023-09-19
Written in-process control procedures
- 4832023-09-19
Complete Test Data
- warning_letter2023-08-04
FDA Warning Letter (drug product)
- 4832022-07-22
Procedures for sterile drug products
- 4832022-07-22
Equipment Design, Size and Location
- 4832022-07-22
Extent of discrepancy, failure investigations
- recall — Class III2018-03-14
Failed Impurities/Degradation Specifications; elevated levels of quality attribute Form L (polymorph).
- 4832018-01-30
Late submission of 15-day report
- 4832017-08-24
Complaint Handling Procedure
- 4832017-08-24
Procedures not in writing, fully followed
- recall — Class I2017-07-19
Presence of Foriegn Tablets/Capsules: customer complaint that an 8-count professional sample bottle labeled as BRILINTA 90 mg tablets contained 5 ZURAMPIC 200 mg tablets, in addition to the expected 8 BRILINTA tablets.
- recall — Class II2016-03-30
Defective Delivery System: Some units have actuation counters set to a number other than 60.
- recall — Class II2015-06-24
Presence of Foreign Tablets/Capsules: Confimed customer compliant by a retail pharmacist that an unopened bottle labeled as NEXIUM¿ capsules contained 60 SEROQUEL¿ XR tablets.
- 4832014-08-27
Written procedures fail to include
- recall — Class II2013-08-14
Presence of Precipitate; potential for incomplete constitution upon addition of diluent.
- 4832013-03-20
Late submission of 15-day report
- 4832011-10-28
Written in-process control procedures
- 4832011-10-28
Absence of Written Procedures
- 4832011-07-05
Investigations of discrepancies, failures
- 4832010-06-23
Written record of investigation incomplete
- 4832010-06-23
Procedures for sterile drug products
- 4832010-06-23
Procedures not in writing, fully followed
- 4832010-06-23
Complaint Investigation/Follow-Up Findings
- 4832010-06-23
Annual visual exams of drug products
- 4832009-12-07
Training--operations, GMPs, written procedures
- 4832009-12-07
Procedures for sterile drug products
- 4832009-12-07
Procedures not in writing, fully followed
- 4832009-12-07
Establishment of time limitations
- 4832009-12-07
Written record of investigation incomplete
- 4832009-12-07
Investigations of discrepancies, failures
- 4832009-12-07
Changes to Procedures Not Reviewed, Approved
- 4832009-12-07
Absence of Written Procedures
- 4832009-06-16
In-process materials specifications
- 4832009-06-16
Procedures for sterile drug products
- 4832009-06-16
Procedure Deviations Recorded and Justified
Is this AstraZeneca Pharmaceuticals LP?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.
Need suppliers found and checked?
The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.